US scientists reports of promising studies on peptide-based cancer vaccine

12 November 2018

GMP News

A team of researchers from the Dr. Rath Research Institute (USA) has developed a cancer vaccine effective in reducing tumor growth.

The study waspublishedin the onlineJournal of Cellular Medicine and Natural Health. The peptide-based vaccine targets specific enzymes calledmetalloproteinases (MMPs)that are necessary for any cancer to grow tumors, metastasize, and form blood vessels in tumors (angiogenesis).

Founded in 2002,The Dr. Rath Health Foundationis a non-profit organization. Dr. Matthias Rath is a renowned scientist and physician. The natural health research is carried out at the Dr. Rath Research Institute (Santa Clara, California, USA).

The Dr. Rath research team showed that test mice, vaccinated with peptides containing specific sequences from MMP-2 and MMP-9 and subsequently challenged with melanoma cancer cells, had an average reduction in tumor volume by about 76% compared to unvaccinated controls. Notably, some vaccinated animals did not develop any cancer at all.

Compared tomonoclonal antibodies (Mabs)or biosimilar molecules recently developed to combat cancer, the antiMMP vaccine approachpromises to be much more effective as well as affordable in the global fight against the disease. While Mabs/biosimilars are directed against one specific type of cancer, the anti-MMP vaccine can target all types of the disease at once. Moreover, while the Mabs/biosimilars generally require an injection once or twice each month, the anti-MMP vaccine would require one single vaccination with potential boosts only after several years.

To protect this valuable technology from being made unaffordable to the majority of patients and nations, the Dr. Rath Research Institute hasobtained patent protectionfor it in many countries.

Print

Shareholders

Read more

Pipeline

Read more

Media Center

Read more